FDA warns on bed-wetting drug

The FDA warned doctors that desmopressin, a drug used to control bed-wetting, can cause some children to have potentially fatal seizures. Because the nasal-spray form of the drug is particularly problematic, the agency revoked its approval for that formulation's use against bed-wetting.

Sold under brand names such as DDAVP, DDVP, and Stimate, among others, desmopressin causes hyponatremia--an abnormally low concentration of sodium in the blood--in certain patients. The agency has received 61 reports of hyponatremic seizures linked to desmopressin, and two deaths.

- see this release
- read the FDA's alert
- here's the FDA's updated information for on desmopressin
- read the WSJ article

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.